05 Nov Cabozantinib Demonstrates Efficacy Against Advanced Renal Cell Carcinoma
Dr. Toni Choueiri
MedicalResearch.com Interview with:
Toni Choueiri, MD
Clinical Director, Lank Center for Genitourinary Oncology
Director, Kidney Cancer Center
Senior Physician
Dana Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Medical Research: What is the background for this study? What are the main findings?
Dr. Choueiri: In the METEOR trial, we aimed to compare cabozantinib, a novel VEGFR, MET, AXL inhibitor to everolimus, a standard 2nd line option in advanced RCC. There is an unmet in this setting. Cabozantinib resulted in a median PFS of 7.4 months compared to 3.8 months with everolimus. Responses also were 4-times higher with cabozantinib-treated patients. At the interim OS analysis, there was a strong trend favoring cabozantinib.
Medical Research: What should clinicians and patients take away from your report?
Dr. Choueiri: Cabozantinib is a valid 2nd line option based on METEOR study results. It is an active drug in the treatment of advanced renal cell carcinoma. We look forward to reporting on the final OS data in 2016.
Medical Research: What recommendations do you have for future research as a result of this study?
Dr. Choueiri: I believe that next generation of research around cabozantinib will include
1) biomarkers studies for efficacy,
2) combination with other agents for an enhanced activity such a immune-checkpoint blockers
Citation:
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
N Engl J Med 2015; 373:1814-1823
November 5, 2015
DOI: 10.1056/NEJMoa1510016
Toni Choueiri, MD (2015). Cabozantinib Demonstrates Efficacy Against Advanced Renal Cell Carcinoma
Last Updated on November 5, 2015 by Marie Benz MD FAAD